ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of SEK 74.79 million. The enterprise value is 70.03 million.
| Market Cap | 74.79M |
| Enterprise Value | 70.03M |
Important Dates
The last earnings date was Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ODI Pharma AB has 18.33 million shares outstanding. The number of shares has increased by 30.78% in one year.
| Current Share Class | 18.33M |
| Shares Outstanding | 18.33M |
| Shares Change (YoY) | +30.78% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 90.83% |
| Owned by Institutions (%) | n/a |
| Float | 1.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| PB Ratio | 38.66 |
| P/TBV Ratio | 38.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -108.19 |
| EV / Sales | 3.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24
| Current Ratio | 1.24 |
| Quick Ratio | 1.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.31 |
Financial Efficiency
Return on equity (ROE) is -54.40% and return on invested capital (ROIC) is -10.52%.
| Return on Equity (ROE) | -54.40% |
| Return on Assets (ROA) | -1.51% |
| Return on Invested Capital (ROIC) | -10.52% |
| Return on Capital Employed (ROCE) | -10.35% |
| Weighted Average Cost of Capital (WACC) | 8.28% |
| Revenue Per Employee | 19.98M |
| Profits Per Employee | -647,258 |
| Employee Count | 1 |
| Asset Turnover | 2.41 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ODI Pharma AB has paid 4,228 in taxes.
| Income Tax | 4,228 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.17% in the last 52 weeks. The beta is 0.73, so ODI Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +72.17% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 2.22 |
| Relative Strength Index (RSI) | 59.48 |
| Average Volume (20 Days) | 16,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of SEK 19.98 million and -647,258 in losses. Loss per share was -0.03.
| Revenue | 19.98M |
| Gross Profit | 5.91M |
| Operating Income | -200,332 |
| Pretax Income | -643,030 |
| Net Income | -647,258 |
| EBITDA | -197,572 |
| EBIT | -200,332 |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 4.76 million in cash and n/a in debt, giving a net cash position of 4.76 million or 0.26 per share.
| Cash & Cash Equivalents | 4.76M |
| Total Debt | n/a |
| Net Cash | 4.76M |
| Net Cash Per Share | 0.26 |
| Equity (Book Value) | 1.93M |
| Book Value Per Share | 0.11 |
| Working Capital | 1.92M |
Cash Flow
| Operating Cash Flow | -386,469 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 29.59%, with operating and profit margins of -1.00% and -3.24%.
| Gross Margin | 29.59% |
| Operating Margin | -1.00% |
| Pretax Margin | -3.22% |
| Profit Margin | -3.24% |
| EBITDA Margin | -0.99% |
| EBIT Margin | -1.00% |
| FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.78% |
| Shareholder Yield | -30.78% |
| Earnings Yield | -0.87% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |